Latest News and Press Releases

Comparative testing against four market-leading hydrogels demonstrates Hydrocelin’s superior shock absorbing capacity Significantly improves the shock-absorbing capacity of pathological equine...

Stephan Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings more than 35 years of strategic and commercial experience in life sciencesAllegro prepares to advance lead...

Allegro’s microparticle hydrogel hydrocelin has the potential to be a first-in-class disease-modifying injectable treatment for osteoarthritisPreclinical study to be presented at WCO conference...

Microparticle hydrogel shows clean systemic toxicity profile over 4 weeks and 13 weeks Treatment designed to restore shock-absorbing capacities of joints in osteoarthritisAllegro plans to start...

Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritisPivotal clinical trial in osteoarthritis patients on track to start in 2025 Liege, Belgium – 4...

Clean systemic toxicity profile and no local side-effects following injection Tiny shock absorbing microparticles support and enhance synovial fluidDesigned as potential first-in-class...